Key result
Intravenous labetalol resulted in a 10% treatment failure rate versus 0% for hydralazine, and a smaller reduction in mean arterial pressure (25.5 vs 33.3 mmHg), but had a more rapid effect.
Why the study?
Does intravenous labetalol compared to hydralazine safely and effectively reduce blood pressure in peripartum patients with severe hypertension?
Population
60 peripartum patients with severe hypertension (diastolic blood pressure ≥110 mmHg)
Comparison
Labetalol via repeated intravenous injections… vs Hydralazine via repeated intravenous injections…
Design
RCT, 2:1 ratio (labetalol to hydralazine)
Follow-up
Acute management (peripartum period)
Authors
Loading...
Labetalol offers faster onset but higher failure and less BP reduction than hydralazine in peripartum hypertension; extends options while questioning equivalence.
RCT (n=60)
2:1 ratio
Does intravenous labetalol compared to hydralazine safely and effectively reduce blood pressure in peripartum patients with severe hypertension?
Absolute Event Rate: 10% vs 0%
Intravenous labetalol is a safe and effective alternative to hydralazine for the acute management of severe peripartum hypertension, offering a more rapid onset of action.
Mabie et al. (1988) conducted an RCT in Severe hypertension complicating pregnancy (n=60). Labetalol vs. Hydralazine (5 mg repeated intravenous injections) was evaluated on Treatment failure. Intravenous labetalol resulted in a 10% treatment failure rate versus 0% for hydralazine, and a smaller reduction in mean arterial pressure (25.5 vs 33.3 mmHg), but had a more rapid effect.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: